News

Moderna (NASDAQ:MRNA) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and renewed pipeline excitement. But the underlying story deserves a closer look. The Moderna Story Has Not Changed Strip away the bounce and the fundamentals tell the same story long-term investors have heard for three ... Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commercial franchises.

Roivant Sciences Ltd (ROIV) strengthens its financial position with a $2.25 billion Moderna settlement and prepares for key drug launches amidst mixed study results.

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in d

On Wednesday, Roivant Sciences Ltd. (NASDAQ:ROIV) posted fourth-quarter adjusted earnings per share of $0.

The Food and Drug Administration is rudderless. Its commissioner, Marty Makary, is gone. The rise of the Make America Healthy Again movement, with its vaccine skepticism and adversarial stance toward drugmakers, has hung over biotech since Robert F. Kennedy Jr. took over at the Department of Health and Human Services.

Roivant Sciences has seen only a marginal shift in its modeled fair value, from US$35.67 to US$35.71, keeping the headline price target effectively stable. That small move reflects a tug of war in analyst commentary, with optimism around the US$2.25b Genevant and Arbutus settlement and key brepocitinib milestones set against questions about how much of this is already in the stock. Read on to see how to track these shifting views and what to watch as the Roivant story continues to...

Wall Street futures were heading deeper into the red ahead of Tuesday's opening bell, as investors remained unconvinced about reports on the latest US-Iran diplomacy efforts. Futures tracking the Nasdaq 100 pointed to an 0.8% drop, while S&P 500 futures were down 0.4% and those for the...

Moderna (MRNA) is back in focus after Phase 3 data showed its mRNA flu vaccine outperformed standard shots in older adults, while separate hantavirus research tied to a cruise ship outbreak added further attention. See our latest analysis for Moderna. The latest flu and hantavirus updates come after a powerful run, with the stock showing a 58.91% year-to-date share price return and a very large 1-year total shareholder return. However, longer-term total shareholder returns over 3 and 5 years...

Investing.com -- Moderna Inc (NASDAQ:MRNA) shares rallied 13% over a multi-day period following reports of a localized Hantavirus outbreak aboard the cruise vessel MV Hondius.

Salesforce (NYSE:CRM) is rolling out new agentic AI deployments across core enterprise workflows. The company has launched Agentforce Contact Center with Ribbon Communications and AI-driven communications integrations at scale. Salesforce has partnered with Moderna to support global operations through Agentforce Life Sciences. The company has also introduced new e-signature integrations with Syncfusion to extend workflow coverage. These moves put Salesforce's AI platform directly into front...

Salesforce Inc. (NYSE:CRM) is one of the cheap stocks to buy for the next 10 years. On April 28, Salesforce and Moderna announced a new partnership to unify the biotech company’s global commercial operations through Agentforce Life Sciences. This collaboration aims to create a single, connected platform that integrates data from sources like SAP and […]

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 10.2% in the afternoon session after the company published positive Phase 3 clinical trial results for its seasonal flu vaccine candidate, mRNA-1010, and announced positive Phase 1 data for its hantavirus vaccine.

These 3 Covid-era stocks set up a 2026 comeback as hantavirus revives the pandemic trade and lifts one player 36% off May lows.

MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.

Evercore ISI analysts said in a note they “see no meaningful revenue opportunity” for Moderna in hantaviruses.

Moderna’s first quarter was marked by a sharp increase in revenue, driven by the fulfillment of large international contracts, particularly through a strategic partnership in the United Kingdom. Management attributed the strong year-over-year growth to international demand for its COVID vaccine products, with CEO Stéphane Bancel noting, “We grew year-over-year revenues significantly to $0.4 billion, driven primarily by execution of our long-term strategic partnership in the U.K.” Despite these g

On May 11, 2026, AI and chip stocks fueled fresh records as surging oil and valuation warnings tested nerves.

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.19%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.29%. June E-mini S&P futures (ESM26 ) rose +0.18%, and June E-mini Nasdaq futures...

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the

A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.

After facing pressure from the summer of 2021 through the end of 2025, Moderna shares have staged an impressive comeback, rallying roughly 50% from their recent lows as investors return their focus to the biotech sector. The rally also received support following reports of a U.S. national testing positive for Hantavirus, as the company disclosed it is exploring an “early-stage and ongoing” treatment program targeting the disease. With those catalysts, let’s examine the technical setup on the daily and monthly charts.

Today, May 11, 2026, AI chip leaders helped steady major U.S. indexes at midday as the Strait of Hormuz remains largely closed.

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

The three major US stock indexes were up slightly in late-morning trading Monday after President Don

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares continued to extend recent gains on Monday as investors welcomed reports that the company is researching a hantavirus vaccine and advancing early-stage work in the area. Shares of Moderna have added more than 16% in the last five days, trading hands...

Moderna shares are rallying following a report the company is researching a hantavirus vaccine.